BioCentury | Apr 15, 2013
Clinical News

Micrologix regulatory update

...been engineered to make, allowing protection for manufacturing almost any biologically active antimicrobial cationic peptide. Micrologix...
BioCentury | Oct 31, 2011
Finance

IPOs on and off

...atopic dermatitis in 2H11. The company has worldwide rights to the antimicrobial bactolysin peptide from BioWest...
BioCentury | Nov 5, 2010
Financial News

Cutanea sets IPO range

...treat rosacea in mid-2011. Cutanea has exclusive, worldwide rights to the antimicrobial bactolysin peptide from BioWest...
BioCentury | Nov 1, 2010
Finance

IPO Watch

...rights to the antimicrobial bactolysin peptide for dermatological uses from BioWest Therapeutics Inc. (TSX:BWE) (formerly Migenix Inc....
BioCentury | Aug 16, 2010
Finance

2nd time the charm?

...rights to the antimicrobial bactolysin peptide for dermatological uses from BioWest Therapeutics Inc. (TSX:BWE) (formerly Migenix Inc....
BioCentury | Aug 13, 2010
Financial News

Cutanea files for IPO

...treat rosacea in mid-2011. Cutanea has exclusive, worldwide rights to the antimicrobial bactolysin peptide from BioWest...
BioCentury | Mar 16, 2009
Clinical News

Omigard: Development discontinued

...posted a 2008 operating loss of $56.5 million. Cadence Pharmaceuticals Inc. (NASDAQ:CADX), San Diego, Calif. Migenix Inc....
BioCentury | Jan 12, 2009
Finance

2009 milestones

...Mid-2009 Cadence (NASDAQ:CADX)/ Bristol-Myers (NYSE:BMY) Acetavance Acute pain and fever Submit NDA 2Q09 Cadence (NASDAQ:CADX)/ Migenix...
BioCentury | Jan 5, 2009
Finance

Phase III & cash constrained

...wrinkles La Jolla (NASDAQ:LJPC) $16.9 $26.1 0.39 Riquent abetimus in Ph III for lupus nephritis Migenix...
BioCentury | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

...I inhibitor from Virogen Ltd., is in Phase II testing to treat chronic HCV infection. Migenix Inc....
Items per page:
1 - 10 of 127
BioCentury | Apr 15, 2013
Clinical News

Micrologix regulatory update

...been engineered to make, allowing protection for manufacturing almost any biologically active antimicrobial cationic peptide. Micrologix...
BioCentury | Oct 31, 2011
Finance

IPOs on and off

...atopic dermatitis in 2H11. The company has worldwide rights to the antimicrobial bactolysin peptide from BioWest...
BioCentury | Nov 5, 2010
Financial News

Cutanea sets IPO range

...treat rosacea in mid-2011. Cutanea has exclusive, worldwide rights to the antimicrobial bactolysin peptide from BioWest...
BioCentury | Nov 1, 2010
Finance

IPO Watch

...rights to the antimicrobial bactolysin peptide for dermatological uses from BioWest Therapeutics Inc. (TSX:BWE) (formerly Migenix Inc....
BioCentury | Aug 16, 2010
Finance

2nd time the charm?

...rights to the antimicrobial bactolysin peptide for dermatological uses from BioWest Therapeutics Inc. (TSX:BWE) (formerly Migenix Inc....
BioCentury | Aug 13, 2010
Financial News

Cutanea files for IPO

...treat rosacea in mid-2011. Cutanea has exclusive, worldwide rights to the antimicrobial bactolysin peptide from BioWest...
BioCentury | Mar 16, 2009
Clinical News

Omigard: Development discontinued

...posted a 2008 operating loss of $56.5 million. Cadence Pharmaceuticals Inc. (NASDAQ:CADX), San Diego, Calif. Migenix Inc....
BioCentury | Jan 12, 2009
Finance

2009 milestones

...Mid-2009 Cadence (NASDAQ:CADX)/ Bristol-Myers (NYSE:BMY) Acetavance Acute pain and fever Submit NDA 2Q09 Cadence (NASDAQ:CADX)/ Migenix...
BioCentury | Jan 5, 2009
Finance

Phase III & cash constrained

...wrinkles La Jolla (NASDAQ:LJPC) $16.9 $26.1 0.39 Riquent abetimus in Ph III for lupus nephritis Migenix...
BioCentury | Sep 25, 2008
Distillery Therapeutics

This Week in Therapeutics

...I inhibitor from Virogen Ltd., is in Phase II testing to treat chronic HCV infection. Migenix Inc....
Items per page:
1 - 10 of 127